Table 2. Univariate and multivariable analysis of predictors of OS in patients treated with first-line therapy for locally advanced or metastatic NSCLC.
| Evaluated variables | Univariate Cox regression | Multivariable cox regression | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (≥70 vs. <70 years) | 1.23 (0.92−1.63) | 0.165 | 1.28 (0.95−1.72) | 0.113 | |
| Gender (F vs. M) | 0.68 (0.50−0.95) | 0.023 | 0.72 (0.51−0.99) | 0.047 | |
| ECOG-PS (≥2 vs. <2) | 2.19 (1.35−3.56) | 0.002 | 1.84 (1.12−3.03) | 0.016 | |
| Smoke status (Y vs. N) | 1.17 (0.81−1.68) | 0.406 | |||
| Tumor stage (IV vs. III) | 1.46 (1.05−2.01) | 0.023 | 1.34 (0.96−1.86) | 0.088 | |
| Histology (non-AC vs. AC) | 1.61 (1.14−2.47) | 0.008 | 0.93 (0.58−1.13) | 0.074 | |
| EGFR status (WT vs. MT) | 0.68 (0.37−1.23) | 0.204 | |||
| SII (≥1,270 vs. <1,270) | 1.97 (1.46−2.65) | <0.001 | 1.98 (1.47−2.68) | <0.001 | |
Y, yes; N, no; AC, adenocarcinoma; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; F, female; HR, hazard ratio; M, male; MT, mutated status; NLR, Neutrophil to lymphocyte ratio; WT, wild-type status; NSCLC, non-small cell lung cancer.